Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3BCHECHRM1CHRM2CHRM3CHRM4CHRNA3CHRNA4CHRNB2CHRNB4ESR1ESR2GABRA1GABRB1GABRG2GBA1GHSRHRH1HTR1DHTR2AMAOBOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8UGCGrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | CA4 | P22748 | 4/20 | 0.43 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL157370 | 0.96 | TSHR (0.47) | LMNATSHRCA4FAHD1CA1 | |
| Cadaverine Tartrate SCHEMBL24913 | 0.96 | LMNA (0.50) | LMNATSHRCA4FAHD1CA1 | |
| Cadaverine Tartrate SCHEMBL409591 | 0.96 | LMNA (0.50) | LMNATSHRCA4FAHD1CA1 | |
| Cadaverine Tartrate SCHEMBL29483921 | 0.96 | LMNA (0.50) | LMNATSHRCA4FAHD1CA1 | |
| Cadaverine Tartrate SCHEMBL30052254 | 0.96 | LMNA (0.50) | LMNATSHRCA4FAHD1CA1 | |
| Cadaverine Tartrate SCHEMBL970332 | 0.92 | TSHR (0.44) | LMNATSHRCA4FAHD1CA1 | |
| Cadaverine Tartrate SCHEMBL7512911 | 0.92 | LMNA (0.48) | LMNATSHRCA4FAHD1CA1 | |
| Cadaverine Tartrate SCHEMBL11878569 | 0.92 | TSHR (0.44) | LMNATSHRCA4FAHD1CA1 | |
| Cadaverine Tartrate SCHEMBL10902649 | 0.92 | LMNA (0.48) | LMNATSHRCA4FAHD1CA1 | |
| Cadaverine Tartrate SCHEMBL5801093 | 0.92 | LMNA (0.48) | LMNATSHRCA4FAHD1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1605 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144843-A1 | Peptide Amide Composition and Preparation Method Therefor | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2026-05-28 | — | — | US | claimed |
| EP-4739687-A1 | STABLE PALIPERIDONE PALMITATE COMPOSITION USING THERMAL TREATMENT | Eugia Pharma Specialities Limited (IN) | 2026-05-13 | — | — | EP | claimed |
| US-12599647-B2 | Peptide amide composition and preparation method therefor | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2026-04-14 | — | — | US | claimed |
| EP-4707350-A1 | TREATMENT LIQUID COMPOSITION FOR DYE PRINTING, INK SET, AND RECORDING METHOD | Seiko Epson Corporation (JP) | 2026-03-11 | — | — | EP | claimed |
| EP-4702974-A1 | OPHTHALMIC COMPOSITION CONTAINING VVN001 | Vivavision Biotech Ltd. (CN) | 2026-03-04 | — | — | EP | claimed |
| EP-4019033-B1 | INJECTABLE SOLUTION COMPRISING A SPIROFUSED TETRAPEPTIDE AN A PH-REGULATOR FOR TREATING KAPPA OPIOID RECEPTOR-ASSOCIATED CONDITIONS | XIZANG HAISCO PHARMACEUTICAL CO LTD (CN) | 2025-06-04 | — | — | EP | claimed |
| CN-120059003-A | Low-odor polyvinyl alcohol and preparation method and application thereof | 中国石油化工股份有限公司 | 2025-05-30 | — | — | CN | claimed |
| WO-2025063737-A1 | METHOD FOR PREPARING SUBSTITUTED FUSED IMIDAZOLE DERIVATIVE | YUNOVIA CO., LTD. (KR) | 2025-03-27 | — | — | WO | claimed |
| EP-3965759-B1 | A TABLET FORMULATION COMPRISING LERCANIDIPINE AND ENALAPRIL | SANOVEL ILAC SANAYI VE TICARET AS (TR) | 2025-02-12 | — | — | EP | claimed |
| WO-2025008726-A1 | STABLE PALIPERIDONE PALMITATE COMPOSITION USING THERMAL TREATMENT | EUGIA PHARMA SPECIALITIES LIMITED (IN) | 2025-01-09 | — | — | WO | claimed |
| US-5462932-A | Aqueous, buffered alendronate solution containing a complexing agent to prevent precipitation; bone loss prevention | MERCK & CO., INC. (US) | 1995-10-31 | — | — | US | claimed |
| EP-0010412-B2 | DENTURE CLEANSING COMPOSITION AND PROCESS FOR ITS PREPARATION | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1987-11-11 | — | — | EP | claimed |
| EP-0010412-B1 | DENTURE CLEANSING COMPOSITION AND PROCESS FOR ITS PREPARATION | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1982-11-03 | — | — | EP | claimed |
| US-4346709-A | Drug delivery devices comprising erodible polymer and erosion rate modifier | ALZA CORPORATION (US) | 1982-08-31 | — | — | US | claimed |
| US-4228033-A | USED IN STEAM REFORMING, CATALYTIC CRACKING OR OXIDATION OF HYDROCARBONS OR ALKANOLS | OSAKA GAS COMPANY, LIMITED (JP) | 1980-10-14 | — | — | US | claimed |
| EP-0010412-A1 | Denture cleansing composition and process for its preparation | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1980-04-30 | — | — | EP | claimed |
| US-4190554-A | DECARBONIZATION, DESULFURIZATION | OSAKA GAS COMPANY, LTD. (JP) | 1980-02-26 | — | — | US | claimed |
| US-4147660-A | Method for reactivation of platinum group metal catalyst with aqueous alkaline and/or reducing solutions | OSAKA GAS COMPANY, LTD. (JP) | 1979-04-03 | — | — | US | claimed |
| US-3994729-A | DIALDEHYDES, FIXING WITH THIOSULFATES, ALUMINUM SALT, TARTARIC ACID OR CITRIC ACID | FUJI PHOTO FILM CO., LTD. (JA) | 1976-11-30 | — | — | US | claimed |
| US-3973967-A | PRINTING PLATES, RESOLUTION | ITEK CORPORATION (US) | 1976-08-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599647-B2 | Peptide amide composition and preparation method therefor | OPRM1, OPRL1, OPRD1 | LMNA 3170/4885TSHR 1116/4885CA4 1124/4885 |
| US-20260144843-A1 | Peptide Amide Composition and Preparation Method Therefor | VIP, NGLY1, NPR1 | LMNA 2506/4885TSHR 1387/4885CA4 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.